Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  CVS Health Corporation    CVS

CVS HEALTH CORPORATION

(CVS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

CVS Health : DOJ sues CVS over 'stale' Omnicare prescription refills

share with twitter share with LinkedIn share with facebook
share via e-mail
12/17/2019 | 04:37pm EST

The federal government is joining a legal fight against CVS Health that accuses its troubled Omnicare business of routinely filling prescriptions that had expired or run out of refills.

The Department of Justice said in federal court papers filed Tuesday that Omnicare’s pharmacies sent drugs to people living in residential facilities based on “stale, invalid prescriptions.” It accused the company of fraudulently billing government-funded programs like Medicaid and Medicare for drugs dispensed without a valid prescription from 2010 to 2018.

The DOJ said the practice put the safety of thousands of patients at risk because people kept taking the same drugs for months — or in some cases, years — without talking to a doctor.

CVS Health spokesman Mike DeAngelis said the claims have no merit and the company plans to “vigorously defend the matter in court.”

“We are confident that Omnicare’s dispensing practices will be found to be consistent with state requirements and industry-accepted practices,” he said.

Omnicare distributes drugs to skilled-nursing and assisted-living facilities across the country. This isn’t its first brush with legal trouble.

In 2016 it agreed to pay more than $28 million to resolve allegations that it accepted kickbacks for pushing an anti-seizure medication on doctors treating nursing home patients.

Two years before that, it agreed to pay more than $124 million to settle lawsuits alleging it gave kickbacks to some facilities so they would keep the company as their drug provider for elderly Medicare and Medicaid recipients.

In the latest case, the DOJ said many of the drugs dispensed by Omnicare without valid prescriptions treated serious, chronic conditions like dementia, depression and heart disease. It said the drugs need to be monitored by doctors, especially when taken with other medications.

“Rather than performing its basic professional obligation as a pharmacy to obtain a new prescription after an old one expired or ran out of refills, Omnicare simply assigned a new number to the old prescription and kept on dispensing,” the complaint stated.

The complaint filed by the U.S. attorney's office in Manhattan said Omnicare management focused on maximizing the number of prescriptions filled instead of putting in place a compliance and training program to support its pharmacy staff.

The federal government is joining two lawsuits that had been filed under seal in federal court.

CVS Health bought Cincinnati-based Omnicare for more than $10 billion in cash in 2015, and CEO Larry Merlo hailed the deal then as a “substantial growth opportunity.” But it has proven to be a financial headache.

CVS Health said earlier this year that it booked a $2.2 billion charge in the final quarter of 2018 from the Omnicare business, which has been dealing with low occupancy rates in skilled nursing locations and the bankruptcy of a major customer.

CVS Health Corp. runs one of the nation's largest drugstore chains and processes well over a billion prescriptions every year as a pharmacy benefit manager. Shares of Woonsocket, Rhode Island, company fell $1.05, or 1.4%, to close Monday at $73.35, while broader indexes climbed slightly.

© 2019 The Canadian Press. All rights reserved., source Canadian Press DataFile

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on CVS HEALTH CORPORATION
02/18CVS HEALTH : Management's Discussion and Analysis of Financial Condition and Res..
AQ
02/14CVS HEALTH : RespireRx Pharmaceuticals CEO Issues Progress and Status Report
AQ
02/13CVS HEALTH : Aetna Medicaid Launches New Approach To Integrated Care Supporting ..
PR
02/13CVS Reaps Benefits of Aetna Deal -- WSJ
DJ
02/13CVS HEALTH : pharmacy business lifted by high prices
AQ
02/12CVS HEALTH : Business Highlights
AQ
02/12Health Care Up As Investors Hedge On Chances Of Coronavirus Cure -- Health Ca..
DJ
02/12CVS Swings to Profit, Forecasts 2020 Results in Line With Estimates -- Update
DJ
02/12GLOBAL MARKETS LIVE: Boeing gets 0 orders in January, Lyft won’t be profitabl..
02/12CVS HEALTH : Q4 2019 Earnings Presentation
PU
More news
Financials (USD)
Sales 2020 263 B
EBIT 2020 15 728 M
Net income 2020 7 271 M
Debt 2020 55 418 M
Yield 2020 2,79%
P/E ratio 2020 12,9x
P/E ratio 2021 11,6x
EV / Sales2020 0,57x
EV / Sales2021 0,53x
Capitalization 93 613 M
Chart CVS HEALTH CORPORATION
Duration : Period :
CVS Health Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CVS HEALTH CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 84,19  $
Last Close Price 71,78  $
Spread / Highest target 51,9%
Spread / Average Target 17,3%
Spread / Lowest Target -1,09%
EPS Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
Eva C. Boratto Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President